ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER CELL CULTURE;
CANCER INHIBITION;
CONTROLLED STUDY;
CYTOTOXICITY;
DRUG SCREENING;
DRUG STRUCTURE;
HUMAN;
HUMAN CELL;
PRIORITY JOURNAL;
STRUCTURE ACTIVITY RELATION;
Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors
Nagarajan M., Morrell A., Fort B.C., Meckley M.R., Antony S., Kholhagen G., et al. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors. J Med Chem 47 (2004) 5651-5661
5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity
Spicer J., Finlay G., Baguley B., Velea L., Graves D., and Denny W. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity. Anti-Cancer Drug Des 14 (1999) 37-45
Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents
Chu D.T.W., Hallas R., Alder J., and Plattner J.J. Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents. Drugs Exp Clin Res 20 (1994) 177-183
Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors
Permana P.A., Snapka R.M., Shen L.L., Chu D.T.W., Clement J.J., and Plattner J.J. Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 33 (1994) 11333-11339
Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group
Robinson M.J., Martin B.A., Gootz T.D., McGuirk P.R., and Osheroff N. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother 36 (1998) 751-756
Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinoline-carboxylic acid and related derivatives
Wentland M.P., Lesher G.Y., Reuman M., Gruett M.D., Singh B., Aldous S.C., et al. Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinoline-carboxylic acid and related derivatives. J Med Chem 36 (1993) 2801-2809
Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria
Emami S., Shafiee A., and Foroumadi A. Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria. Mini-Rev Med Chem 6 (2006) 375-386
Shafiee A, Haddad-Zahmatkesh M, Mohammadhosseini N, Khalafy J, Emami S, Mansouri S, et al. Synthesis and in-vitro antibacterial activity of N-piperazinyl quinolone derivatives with 2-(5-chloro-2-thienyl)ethyl residue. Daru 2008; 16: in press.
Shafiee A, Haddad-Zahmatkesh M, Mohammadhosseini N, Khalafy J, Emami S, Mansouri S, et al. Synthesis and in-vitro antibacterial activity of N-piperazinyl quinolone derivatives with 2-(5-chloro-2-thienyl)ethyl residue. Daru 2008; 16: in press.
14
0021061819
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position
Inagaki H., Takahashi H., and Takemura M. Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position. Bioorg Med Chem Lett 14 (2004) 5193-5198
Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde
Anderson V.E., and Osheroff N. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Pharm Design 7 (2001) 339-353
Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase
Alovero F., Pan X.-S., Morris J.E., Manzo R.H., and Fisher L.M. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother 44 (2000) 320-325
